AIM ImmunoTech (NYSEAMERICAN:AIM) Shares Down 7.8% – Here’s Why

Shares of AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) dropped 7.8% on Monday . The company traded as low as $0.26 and last traded at $0.2630. Approximately 1,836,691 shares traded hands during mid-day trading, an increase of 48% from the average daily volume of 1,242,926 shares. The stock had previously closed at $0.2854.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets decreased their price target on shares of AIM ImmunoTech from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $9.00.

AIM ImmunoTech Trading Down 7.8%

The stock has a market cap of $3.83 million, a PE ratio of -0.08 and a beta of 1.20. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.01 and a current ratio of 1.01. The stock has a fifty day moving average price of $0.34 and a 200 day moving average price of $0.59.

AIM ImmunoTech (NYSEAMERICAN:AIM) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.43) earnings per share for the quarter. The company had revenue of $0.03 million during the quarter. Equities analysts expect that AIM ImmunoTech Inc. will post -0.63 EPS for the current year.

Institutional Investors Weigh In On AIM ImmunoTech

A hedge fund recently raised its position in AIM ImmunoTech stock. DRW Securities LLC increased its position in shares of AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) by 60.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 69,545 shares of the company’s stock after purchasing an additional 26,254 shares during the period. DRW Securities LLC owned approximately 2.12% of AIM ImmunoTech worth $79,000 at the end of the most recent quarter. Institutional investors and hedge funds own 12.02% of the company’s stock.

AIM ImmunoTech Company Profile

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.